Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies

Hirsch, 2017, Lung cancer: current therapies and new targeted treatments, Lancet, 389, 299, 10.1016/S0140-6736(16)30958-8 FDA, 2021 Marcus, 2019, FDA Approval Summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors, Clin. Cancer Res., 25, 3753, 10.1158/1078-0432.CCR-18-4070 Marcus, 2021, FDA Approval Summary: pembrolizumab for the treatment of tumor mutational burden–high solid tumors, Clin. Cancer Res., 27, 4685, 10.1158/1078-0432.CCR-21-0327 Marcus, 2021, FDA Approval Summary: entrectinib for the treatment of NTRK gene fusion solid tumors, Clin. Cancer Res., 27, 928, 10.1158/1078-0432.CCR-20-2771 FDA, 2018 Cocco, 2018, NTRK fusion-positive cancers and TRK inhibitor therapy, Nat. Rev. Clin. Oncol., 15, 731, 10.1038/s41571-018-0113-0 Cocco, 2019, Colorectal carcinomas containing hypermethylated MLH1 promoter and wild type BRAF/KRAS are enriched for targetable kinase fusions, Cancer Res., 79, 1047, 10.1158/0008-5472.CAN-18-3126 Bocciarelli, 2021, MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories, Hum. Pathol., 114, 99, 10.1016/j.humpath.2021.05.006 Yonemaru, 2021, NTRK fusion-positive colorectal cancer in Japanese population, Pathol. Int., 71, 355, 10.1111/pin.13082 Chou, 2020, NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases, Mod. Pathol., 33, 924, 10.1038/s41379-019-0417-3 Ross, 2014, New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing, Oncologist, 19, 235, 10.1634/theoncologist.2013-0352 Allen, 2021, Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature, J. Clin. Pathol. Forsythe, 2020, A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors, Ther. Adv. Med. Oncol., 12, 10.1177/1758835920975613 Arnold, 2019, Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry, Pathol. Res. Pract., 215, 10.1016/j.prp.2019.152662 Aref-Eshghi, 2021, The oncogenic roles of NTRK fusions and methods of molecular diagnosis, Cancer Genet., 258–259, 110, 10.1016/j.cancergen.2021.10.005 Solomon, 2020, NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls, Mod. Pathol., 33, 38, 10.1038/s41379-019-0324-7 Hechtman, 2017, Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions, Am. J. Surg. Pathol., 41, 1547, 10.1097/PAS.0000000000000911 Drilon, 2018, Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children, N. Engl. J. Med., 378, 731, 10.1056/NEJMoa1714448 Hong, 2021, Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer, J. Clin. Oncol., 39, 3108, 10.1200/JCO.2021.39.15_suppl.3108 Demetri, 2022, Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors, Clin. Cancer Res., 28, 1302, 10.1158/1078-0432.CCR-21-3597 Buza, 2016, Mismatch repair deficiency testing in clinical practice, Expert. Rev. Mol. Diagn., 16, 591, 10.1586/14737159.2016.1156533 Morris, 2018, Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform, PLoS ONE, 13 Win, 2017, Prevalence and penetrance of major genes and polygenes for colorectal cancer, Cancer Epidemiol. Biomark., 26, 404, 10.1158/1055-9965.EPI-16-0693 Poulogiannis, 2010, DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome, Histopathology, 56, 167, 10.1111/j.1365-2559.2009.03392.x Bonneville, 2017, Landscape of microsatellite instability across 39 cancer types, JCO Precis. Oncol., 2017 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733 Marabelle, 2020, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study, J. Clin. Oncol., 38, 1, 10.1200/JCO.19.02105 Le, 2020, Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164, J. Clin. Oncol., 38, 11, 10.1200/JCO.19.02107 Andre, 2021, Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study, J. Clin. Oncol., 39, 9, 10.1200/JCO.2021.39.3_suppl.9 Goodman, 2017, Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers, Mol. Cancer Ther., 16, 2598, 10.1158/1535-7163.MCT-17-0386 Klempner, 2020, Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence, Oncologist, 25, e147, 10.1634/theoncologist.2019-0244 Merino, 2020, Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project, J. Immunother. Cancer, 8, 10.1136/jitc-2019-000147 Vega, 2021, Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project, Ann. Oncol., 32, 1626, 10.1016/j.annonc.2021.09.016 Sha, 2020, Tumor mutational burden (TMB) as a predictive biomarker in solid tumors, Cancer Discov., 10, 1808, 10.1158/2159-8290.CD-20-0522 Chalmers, 2017, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med., 9, 34, 10.1186/s13073-017-0424-2 Salem, 2018, Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers, Mol. Cancer Res., 16, 805, 10.1158/1541-7786.MCR-17-0735 Keshinro, 2021, Tumor-infiltrating lymphocytes, tumor mutational burden, and genetic alterations in microsatellite unstable, microsatellite stable, or mutant POLE/POLD1 colon cancer, JCO Precis. Oncol., 5 Marabelle, 2020, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, Lancet Oncol., 21, 1353, 10.1016/S1470-2045(20)30445-9 Cristescu, 2020, Abstract LB-261: Association between tumor mutational burden (TMB) assessed by whole-exome sequencing (WES) and outcomes of pembrolizumab (pembro) monotherapy, Cancer Res., 80, LB-261, 10.1158/1538-7445.AM2020-LB-261 Goodman, 2019, Microsatellite-stable tumors with high mutational burden benefit from immunotherapy, Cancer Immunol. Res., 7, 1570, 10.1158/2326-6066.CIR-19-0149 Wang, 2019, Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432, Ann. Oncol., 30, 1479, 10.1093/annonc/mdz197 Fabrizio, 2018, Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition, J. Gastrointest. Oncol., 9, 610, 10.21037/jgo.2018.05.06 Palmeri, 2021, Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers, ESMO Open, 7 Subbiah, 2020, Pan-cancer efficacy of vemurafenib in BRAF V600-mutant non-melanoma cancers, Cancer Discov., 10, 657, 10.1158/2159-8290.CD-19-1265 Hyman, 2015, Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations, N. Engl. J. Med., 373, 726, 10.1056/NEJMoa1502309 Adashek, 2022, Tissue-agnostic activity of BRAF plus MEK inhibitor in BRAF V600-mutant tumors, Mol. Cancer Ther., 21, 871, 10.1158/1535-7163.MCT-21-0950 Kopetz, 2019, Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer, N. Engl. J. Med., 381, 1632, 10.1056/NEJMoa1908075 Subbiah, 2020, Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial, Lancet Oncol., 21, 1234, 10.1016/S1470-2045(20)30321-1 Salama, 2020, Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H, J. Clin. Oncol., 38, 3895, 10.1200/JCO.20.00762 Oh, 2020, HER2-targeted therapies — a role beyond breast cancer, Nat. Rev. Clin. Oncol., 17, 33, 10.1038/s41571-019-0268-3 Wolff, 2018, Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update, J. Clin. Oncol., 36, 2105, 10.1200/JCO.2018.77.8738 Gupta, 2022, Therapeutic landscape of advanced HER2-positive breast cancer in 2022, Med. Oncol., 39, 258, 10.1007/s12032-022-01849-y Meric-Bernstam, 2019, Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer, Clin. Cancer Res., 25, 2033, 10.1158/1078-0432.CCR-18-2275 Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X Thuss-Patience, 2017, Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study, Lancet Oncol., 18, 640, 10.1016/S1470-2045(17)30111-0 Shitara, 2020, Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer, N. Engl. J. Med., 382, 2419, 10.1056/NEJMoa2004413 Strickler, 2021, MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress, J. Clin. Oncol., 39, TPS252, 10.1200/JCO.2021.39.3_suppl.TPS252 Meric-Bernstam, 2019, Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study, Lancet Oncol., 20, 518, 10.1016/S1470-2045(18)30904-5 Siena, 2021, Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial, Lancet Oncol., 22, 779, 10.1016/S1470-2045(21)00086-3 Javle, 2021, Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study, Lancet Oncol., 22, 1290, 10.1016/S1470-2045(21)00336-3 Ohba, 2022, Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial), J. Clin. Oncol., 40, 4006, 10.1200/JCO.2022.40.16_suppl.4006 Subbiah, 2020, State-of-the-art strategies for targeting RET-dependent cancers, J. Clin. Oncol., 38, 1209, 10.1200/JCO.19.02551 Le Rolle, 2015, Identification and characterization of RET fusions in advanced colorectal cancer, Oncotarget, 6, 28929, 10.18632/oncotarget.4325 Kato, 2017, RET Aberrations in diverse cancers: next-generation sequencing of 4,871 patients, Clin. Cancer Res., 23, 1988, 10.1158/1078-0432.CCR-16-1679 Wirth, 2020, Efficacy of selpercatinib in RET-altered thyroid cancers, N. Engl. J. Med., 383, 825, 10.1056/NEJMoa2005651 Drilon, 2020, Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer, N. Engl. J. Med., 383, 813, 10.1056/NEJMoa2005653 Subbiah, 2022, Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial, Lancet Oncol., 23, 1261, 10.1016/S1470-2045(22)00541-1 Subbiah, 2022, Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial, Nat. Med., 28, 1640, 10.1038/s41591-022-01931-y Li, 2019, RET fusions in solid tumors, Cancer Treat. Rev., 81, 10.1016/j.ctrv.2019.101911 Nagasaka, 2022, NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis, Trends Cancer, 8, 242, 10.1016/j.trecan.2021.11.003 Jonna, 2019, Detection of NRG1 gene fusions in solid tumors, Clin. Cancer Res., 25, 4966, 10.1158/1078-0432.CCR-19-0160 Cadranel, 2021, Therapeutic potential of afatinib in NRG1 fusion-driven solid tumors: a case series, Oncologist, 26, 7, 10.1634/theoncologist.2020-0379 Jones, 2019, NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma, Clin. Cancer Res., 25, 4674, 10.1158/1078-0432.CCR-19-0191 Schram, 2021, Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions, J. Clin. Oncol., 39, 3003, 10.1200/JCO.2021.39.15_suppl.3003 Helsten, 2016, The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation Sequencing, Clin. Cancer Res., 22, 259, 10.1158/1078-0432.CCR-14-3212 Abou-Alfa, 2020, Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study, Lancet Oncol., 21, 671, 10.1016/S1470-2045(20)30109-1 Javle, 2021, Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study, Lancet Gastroenterol. Hepatol., 6, 803, 10.1016/S2468-1253(21)00196-5 Subbiah, 2022, FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies, Ann. Oncol., 33, 522, 10.1016/j.annonc.2022.02.001 Meric-Bernstam, 2022, Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a Phase I dose-expansion study, Cancer Discov., 12, 402, 10.1158/2159-8290.CD-21-0697 Tsimafeyeu, 2021, 39P Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: a phase Ib study in patients with advanced gastric cancer (RPT835GC1B), Ann. Oncol., 32, S16, 10.1016/j.annonc.2021.01.054 Catenacci, 2021, FIGHT: a randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC), J. Clin. Oncol., 39, 4010, 10.1200/JCO.2021.39.15_suppl.4010